XML 61 R51.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaboration and Licensing Agreements - Narrative (Details) |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | ---
Oct. 01, 2021 | Jul. 31, 2024 USD ($) | Oct. 31, 2021 USD ($) | Feb. 28, 2019 USD ($) | Jan. 31, 2013 program | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2019 target | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($)
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Receivable |  |  |  |  |  | $ 35,923,000 |  |  | $ 35,923,000 |  | $ 23,739,000
Unrealized gain (loss) on equity securities |  |  |  |  |  | (10,015,000) | $ 288,000 |  | (10,529,000) | $ (2,610,000) |
Impairment on equity securities |  |  |  |  |  | (220,000) | 0 |  | 20,430,000 | 0 |
Deferred revenue |  |  |  |  |  | 0 | 7,900,000 |  | 0 | 7,900,000 |
Collaborations, milestones, and royalties |  |  |  |  |  | 23,907,000 | 45,523,000 |  | 39,904,000 | 64,485,000 |
Royalties |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 0 | 13,300,000 |  | 100,000 | 27,000,000.0 |
Milestone |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 0 | 10,000,000.0 |  | 500,000 | 15,000,000.0 |
Alexion |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 13,800,000 | 11,200,000 |  | 26,400,000 | 21,600,000 |
MorphoSys |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 1,600,000 | 2,000,000.0 |  | 4,400,000 | 3,900,000 |
Mabgeek |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 1,500,000 | 0 |  | 1,500,000 | 0 |
Vir |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 0 | 100,000 |  | 100,000 | 1,500,000 |
Zenas |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Impairment on equity securities |  |  |  |  |  |  | 0 |  | 20,400,000 | 0 |
Collaborations, milestones, and royalties |  |  |  |  |  | 0 | 10,000,000.0 |  | 0 | 10,000,000.0 |
Zenas | Preferred Stock |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Equity shares estimated fair value |  |  |  |  |  | 43,780,000 |  |  | 43,780,000 |  | 64,210,000
Third Party Licensee |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 7,000,000.0 | 0 |  | 7,000,000.0 | 0 |
Option and License agreement | Alexion |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Number of different target programs | program |  |  |  |  | 1 |  |  |  |  |  |
Receivable |  |  |  |  |  | 13,800,000 |  |  | 13,800,000 |  |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
Option and License agreement | Alexion | Royalties |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 13,800,000 | 11,200,000 |  | 26,400,000 | 21,600,000 |
Technology License Agreement | Mabgeek |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 1,500,000 |  |  | 1,500,000 |  |
Technology License Agreement | Vega |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  | $ 500,000 |  |  |  |  |  |  |  |
Collaborations, milestones, and royalties |  |  |  |  |  | 0 | 0 |  | 500,000 | 0 |
Technology License Agreement | Gale |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  | 7,500,000 |  |  | 7,500,000 |  |
Service agreement charges |  |  |  |  |  | 4,600,000 |  |  | 8,000,000.0 |  |
Technology License Agreement | Gale | Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Payments for repurchase of preferred stock and preference stock |  | $ 3,000,000.0 |  |  |  |  |  |  |  |  |
Collaboration and License Agreement | Genentech |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 0 | 0 |  | 0 | 0 |
Initial cost-sharing percentage |  |  |  | 45.00% |  |  |  |  |  |  |
Royalty milestones |  |  |  | $ 600,000,000 |  |  |  |  |  |  |
Collaboration and License Agreement | Genentech | Development-based |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Royalty milestones |  |  |  | 115,000,000 |  |  |  |  |  |  |
Collaboration and License Agreement | Genentech | Regulatory-based |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Royalty milestones |  |  |  | 185,000,000 |  |  |  |  |  |  |
Collaboration and License Agreement | Genentech | Sales-based |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Royalty milestones |  |  |  | $ 300,000,000 |  |  |  |  |  |  |
Collaboration and License Agreement | Genentech | XmAb24306 |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement receivable (payable) related to cost sharing development activities |  |  |  |  |  | (7,600,000) |  |  | (7,600,000) |  |
Collaboration and License Agreement | Genentech | Research service |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
Collaboration and License Agreement | Janssen |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 0 | 0 |  | 0 | 0 |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
Collaboration and License Agreement | MorphoSys |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
Collaboration and License Agreement | MorphoSys | Royalties |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 1,600,000 | 2,000,000.0 |  | 4,400,000 | 3,900,000 |
Receivable |  |  |  |  |  | 2,100,000 |  |  | 2,100,000 |  |
License | Zenas |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 0 | 10,000,000.0 |  | 0 | 10,000,000.0 |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
License | Zenas | Milestone | Preferred Stock |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Equity shares estimated fair value |  |  |  |  |  |  |  |  |  |  | $ 10,000,000.0
Second Collaboration And License Agreement | Janssen |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 0 | 22,200,000 |  | 0 | 27,500,000 |
Receivable |  |  |  |  |  | 5,200,000 |  |  | 5,200,000 |  |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
Research license term | 2 years |  |  |  |  |  |  |  |  |  |
Second Collaboration And License Agreement | Janssen | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Percentage of responsibility for development costs | 20.00% |  |  |  |  |  |  |  |  |  |
Second Collaboration And License Agreement | Janssen | Minimum |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Share development percentage | 80.00% |  |  |  |  |  |  |  |  |  |
Patent License Agreement | Vir |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Number of different target programs | target |  |  |  |  |  |  |  | 2 |  |  |
Receivable |  |  |  |  |  | 0 |  |  | 0 |  |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
Patent License Agreement | Vir | Royalties |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | $ 100,000 |  | 100,000 | $ 1,500,000 |
Patent License Agreement | Third Party Licensee |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |
Receivable |  |  |  |  |  | 7,000,000.0 |  |  | 7,000,000.0 |  |
Deferred revenue |  |  |  |  |  | 0 |  |  | 0 |  |
Collaborations, milestones, and royalties |  |  |  |  |  | $ 7,000,000.0 |  |  | $ 7,000,000.0 |  |

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of impairment loss on investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow to reacquire preferred stock during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Service Agreement Charges + References No definition available. + Details
Name: | xncr_CollaborationAgreementServiceAgreementCharges
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of responsibility assumed for development costs, if the company elects to participate in development. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementPercentageOfResponsibilityAssumedForDevelopmentCosts
Namespace Prefix: | xncr_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of share assumed by the counter-party for development costs. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementSharePercentageOfDevelopmentCostByCounterparty
Namespace Prefix: | xncr_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of different target programs under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfTargetPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of receivable (payable) within a collaborative agreement that is associated with cost-sharing development activities. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementReceivablePayableRelatedToCostSharingDevelopmentActivities
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the research license term under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementResearchLicenseTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Transaction Price + References No definition available. + Details
Name: | xncr_CollaborativeArrangementTransactionPrice
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The initial cost-sharing percentage. + References No definition available. + Details
Name: | xncr_InitialCostSharingPercentage
Namespace Prefix: | xncr_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. + References No definition available. + Details
Name: | xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_MilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_ShanghaiMabgeekBiotechCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_VirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_ZenasBioPharmaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_ThirdPartyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_OptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_TechnologyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_VegaTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_GaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_GenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_Xmab24306ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_ResearchActivityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_SecondCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_PatentLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |